Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q13639
UPID:
5HT4R_HUMAN
Alternative names:
Serotonin receptor 4
Alternative UPACC:
Q13639; C4WYH4; Q546Q1; Q684M0; Q712M9; Q96KH9; Q96KI0; Q9H199; Q9NY73; Q9UBM6; Q9UBT4; Q9UE22; Q9UE23; Q9UQR6
Background:
The 5-hydroxytryptamine receptor 4, also known as the Serotonin receptor 4, plays a pivotal role in neurotransmission and hormonal regulation. It is activated by serotonin, a key neurotransmitter and hormone involved in mood, appetite, and sleep. The receptor's activity is mediated by G proteins that stimulate adenylate cyclase, highlighting its importance in cellular signaling pathways.
Therapeutic significance:
Understanding the role of 5-hydroxytryptamine receptor 4 could open doors to potential therapeutic strategies. Its involvement in critical neurotransmitter and hormonal pathways makes it a promising target for treating disorders related to mood, appetite, and sleep regulation.